Aaron Royston, M.D., M.B.A. is a Managing Partner at venBio. He has more than 15 years of experience in life sciences investing, company formation and operations, strategic and product planning in the biotechnology industry, and clinical research.
He has been involved in launching and investing in a number of venBio companies including Apellis Pharmaceuticals (IPO 2017), Menlo Therapeutics (IPO 2018), Akero Therapeutics (IPO 2019), Harmony Biosciences (IPO 2020), Impel NeuroPharma (IPO 2021), Ventyx BioSciences (IPO 2021), RayzeBio, Ablaze Pharmaeuticals, 35Pharma, Attovia Therapeutics, HistoWiz, and Swift Health Systems. These companies’ efforts have led to five FDA drug approvals.
1700 Owens Street, Suite 595
San Francisco, CA 94158
1200 Westlake Ave N, Suite 900
Seattle, WA 98109
© 2023 venBio. All Rights Reserved.